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EPIDEMIOLOGY AND PATHOLOGY
In South Africa a national community-based survey suggests
that HIV prevalence in the general population is close to 12%
(12.8% in females and 9.5% in males).1 Equally alarming is the
finding that an estimated 15.7% of health workers employed
in the public and private health facilities located in four South
African provinces are infected with HIV/AIDS.2 Chronic kidney
disease develops in 2 - 10% of patients and risk factors include
African descent, male gender, and a concomitant diagnosis of
diabetes or hypertension and proteinuria.3 The development of
HIVAN has definitively been linked to renal cellular infection
and focal segmental glomerulosclerosis appears to be the
commonest glomerular pathology. The fact that the disease
typically affects men of African descent has obvious
consequences in the South African context. 
PRE-DIALYSIS
There appears to be a high prevalence of proteinuria on the
first urine analysis obtained after HIV documentation.4 Early
treatment with HAART and angiotensin-converting enzyme
(ACE) inhibition may offer long-term renal survival benefits in
HIVAN, and in addition some clinicians have used low-dose
steroids.
RENAL REPLACEMENT THERAPY
Despite rates of EKD in the general population in South
Africa estimated to be about 400 per million population (pmp),
only 99 pmp receive RRT.5 For this reason patients suffering
from HIV and EKD are excluded from long-term dialysis
programmes. Such exclusions may be based on historical
grounds, as previously survival was poor, and on fear of cross-
infection to other dialysis patients and dialysis staff. More
recently the survival of HIV-positive patients has improved and
is often equal to or better than those not infected with HIV.6
HAEMODIALYSIS
The risk of nosocomial HIV infection to health workers in the
dialysis setting is a concern owing to the nature of needle
access for haemodialysis (HD). The risk of infection from
percutaneous exposure to infected blood is 0.3%.
Initial misinformation and panic regarding acquisition of HIV
created great concern, and extreme precautions against the
infection were taken. Dialysis units treating infected patients
often resembled a set from a science fiction movie, with staff
wearing caps, gowns, masks and booties and most patients
being strictly isolated with their own dedicated dialysis
machines. Some shared machines with patients infected with
highly infectious hepatitis B! The more modern approach
proposed by the Centers for Disease Control (CDC) in the USA
stresses the adoption of universal blood and body fluid
precautions, standard disinfection and sterilisation strategies
during dialysis, and careful control of dialyser re-use where
practised. Dialysis machines should not be shared between
patients with HIV and those infected with hepatitis B, and
isolation of HIV-infected patients and dedicated machine use
is currently not recommended by the CDC or the National
Kidney Foundation (NKF) task force on dialysis.
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According to UNAIDS data there are 40 million HIV-infected people around the globe. An uncommon complication of HIV is
HIV-associated nephropathy (HIVAN), and this condition is expected to be one of the leading causes of end-stage kidney
disease (EKD) in black men in the new millennium. Patients present with an immune complex glomerulopathy and focal
segmental glomerulosclerosis together with proteinuria and haematuria and occasionally severe hypertension. Peripheral
oedema is unusual. In the era before antiretroviral therapy (ART) the median survival in the HIV-infected population on dialysis
was 10 months. However, since the introduction of highly active antiretroviral therapy (HAART) and optimal prevention of
opportunistic infections, a life expectancy of 10 - 20 years can be expected. Unfortunately patients infected with HIV are often
excluded from renal replacement therapy (RRT) programmes despite such encouraging outcomes and despite the fact that the
outcome of renal transplantation in HIV patients is comparable to that in HIV-negative recipients at 1-year follow-up in
experienced centres. In the South African context HIV/AIDS has an alarming prevalence, although dialysis and transplantation
are offered only to very few and often only in the acute state. In the light of the new data, HIV seropositivity (especially when
the patient is receiving HAART) needs to be reconsidered as an absolute contraindication to renal replacement.
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In the pre-HAART era survival of HIV-infected patients was
dismal to the point at which it was an ethical dilemma
whether chronic dialysis should be offered to these patients.
However, with the use of HAART the survival of HIV-infected
patients on dialysis has improved considerably. Importantly
however, it has been suggested that HD may activate HIV
replication, although considering the potent antiretroviral
(ARV) activity of the newer HIV drugs activation of HIV seems
unlikely. 
PERITONEAL DIALYSIS
Theoretically peritoneal dialysis (PD) poses less risk than HD to
dialysis staff and other patients as PD fluid is less infectious
than blood. The glucose load provided by PD fluid affords the
patient an adequate caloric load, although protein losses may
actually worsen the patient’s nutritional status. Survival rates
are comparable to those for patients receiving HD.
Controversy abounds regarding a supposed increased risk of
peritonitis, especially when the patient is in an
immunocompromised state. Studies have shown increased
rates of Pseudomonas and fungal infections.6 Once the
expected immune reconstitution on HAART occurs, the risk of
peritonitis falls to that in patients not infected with HIV.
Adequate disinfection protocols are essential when
performing PD as both HIV p24 antigen and HIV antibodies
have been found in PD fluid.
Both HD and PD are effective modalities of RRT in the HIV-
infected EKD patient. The choice of modality should depend on
the individual’s lifestyle and availability of adequate family
support and medical expertise. A prerequisite is that such
patients should receive optimal ART.
HIV seropositivity should not be a negative dialysis criterion.
Patients with HIVAN and EKD should be allowed to choose a
specific dialysis modality, because it is not a factor in
predicting survival.7 When progression to kidney failure is
suspected timely fashioning of an arteriovenous fistula should
be considered, as well as the placement of a PD catheter.
Temporary HD lines are best avoided in those patients with
EKD as long-term vascular access may often be compromised
by such catheters.
TRANSPLANTATION
The arguments in favour of transplantation for HIV-infected
patients have gained a new impetus with improvement in
survival on HAART. In the South African context experience
with transplantation in HIV-positive patients is limited. Major
issues in this regard include:
■ false-positive tests for HIV pre- and post-transplantation
■ transmission of HIV infection through the allograft
■ outcomes of HIV-positive patients who undergo
transplants, and
■ acquisition of HIV-infection following transplantation.
Interestingly, immunosuppressive agents such as cyclosporin
and tacrolimus may retard replication of HIV virus, and
mycophenolate mofetil may potentiate the ARV effect of
commonly used HIV drugs.9
There is a concern regarding the drug-drug interactions
between protease inhibitors and calcineurin inhibitors, and
vigilant drug level monitoring is imperative.10 Although
relatively few patients with HIV currently undergo organ
transplantation, patient and graft survival are comparable to
United Network for Organ Sharing (UNOS) figures at 1 year of
follow-up. Furthermore, there is no evidence of progression of
HIV disease, and as experience grows in this field
asymptomatic HIV-infected patients with ESRD may be
offered this most optimal of renal replacement therapies. 
Adequate and accurate testing of any cadaveric or living
allograft for HIV infection, especially in high-risk populations,
ANAEMIA
Anaemia is common in HIV-infected patients with renal
disease, and overall anaemia is the commonest
haematological abnormality in HIV-infected patients. Mean
haematocrit levels in patients with HIVAN are lower than in
other patients with end-stage renal disease (ESRD) starting
dialysis. HIV infections may exacerbate anaemia in patients
with kidney disease by direct effects of HIV infection on
erythropoiesis, opportunistic infections, ARV drugs, and other
rare mechanisms such as thrombotic microangiopathies.
Such anaemia is independent of other factors associated
with shorter survival and it should be managed as
aggressively, e.g. with recombinant human erythropoietin
(EPO), which is utilised for any patient with EKD. HIV-positive
patients often require higher doses of EPO to maintain
adequate haemoglobin levels. Although rare, parvovirus B19
infection should be suspected if anaemia in the HIV-infected
patient does not respond to EPO and other causes have been
ruled out. Iron is essential for haemoglobin formation and
iron status should be monitored and corrected accordingly by
the percent transferrin saturation and serum ferritin levels. In
this situation it is important to realise that ferritin levels are
often elevated in patients with HIV infection as a marker of
inflammation, and high iron stores may also adversely
influence outcome in HIV-infected patients. Some studies
have shown that oxidative stress and iron may activate 
HIV-1, and when intravenous administration of iron is carried
out, viral loads need to be monitored.
VACCINATION 
The immunosuppression that results from HIV infection and
uraemia is likely to lead to suboptimal response to
vaccination. Immunisation for hepatitis B in HIV-infected
EKD patients is important because not only does hepatitis B
virus infection occur more frequently in HIV-positive
subjects, but these patients also are more likely to develop
chronic hepatitis B infection. Unfortunately, however,
antibody response to hepatitis vaccination is impaired in
HIV-infected patients, only half of whom develop a
protective antibody response.8
GENERAL PATIENT MANAGEMENT
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reduces the risk of transmission to the recipient although such
infections do occur.
An adequately functioning allograft restores sexual and
reproductive function in the recipient of any kidney allograft,
and in parts of the world where the prevalence of HIV is high
(such as in South Africa) HIV infection following
transplantation is a real concern.11
ISSUES RELATED TO HAART
The aim of ART in EKD patients with HIV should be to
reduce the viral load to undetectable levels and to prevent
opportunistic infections. With the use of HAART, improved
prophylaxis and treatment of opportunistic infections there
has been a dramatic improvement in survival of HIV-infected
patients, although such therapy is often under-utilised in HIV-
infected patients with EKD.10
There are three main groups of ARV drugs, nucleoside and
non-nucleoside reverse transcriptase inhibitors (NRTIs and
NNRTIs) and protease inhibitors (PIs). In most patients a
combination of either two NRTIs with a PI or two NRTIs plus
one NNRTI are used. NRTIs used in HIV therapy are primarily
excreted by the kidneys, so the dose administered to EKD
patients is 30 - 50% of the normal dose for various drugs (see
Table I). In addition, on dialysis days the NRTIs should be given
after dialysis. Abacavir is the only NRTI the absorption,
elimination and distribution phases of which are not altered
by renal insufficiency and which does not need dose
adjustment in patients with ESRD. Since abacavir is mainly
metabolised in the liver, the fraction removed during dialysis is
not clinically significant, and it can be administered at any
time on dialysis days. NNRTIs and PIs are mainly metabolised
in the liver by cytochrome P450 isoenzymes, and do not need
dose adjustments in patients with ESRD. NNRTIs should be
administered after haemodialysis to minimise loss during
dialysis. In contrast, PIs can be administered regardless of the
dialysis schedule. Table I details dosage adjustments of ARV
agents required in patients with kidney insufficiency.12
Use of ARV drugs is a double-edged sword in that despite their
positive antiviral properties their use results in a number of
renal abnormalities. Table II details such effects.13
GENERAL MEASURES
Nephrologists and physicians taking care of HIV-infected
ESRD patients need to be aware of the special issues relevant
to HIV-infected patients with ESRD and should co-operate
actively with HIV specialists to improve the outcome and
quality of life of this group of patients. Prophylaxis against
Pneumocystis jiroveci pneumonia, tuberculosis and cyto-
megalovirus (CMV) in the transplant patient are imperative,
while surveillance and early intervention for Kaposi’s sarcoma
and other malignancies is also important. 
CONCLUSIONS
HIV/AIDS is reaching epidemic proportions in southern Africa.
With the positive governmental move towards widespread
availability of ARV drugs, clinicians are encouraged to gain a
sound knowledge of the effects of these agents in patients
with and without kidney failure. RRT should be available for
Haemodialysed 
Drug Normal dosage patients 
NRTIs
Zidovudine* 200 mg tds 100 mg tds
Didanosine* 200 mg bd 200 mg daily
Zalcitabine* 0.75 mg tds 0.75 mg qd
Stavudine* 40 mg bd 40 mg daily
Lamivudine* 150 mg bd 150 mg stat then 
250 mg q 24 h
Abacavir* 600 mg bd Normal dosage
NNRTIs
Nevirapine* 200 mg daily for Normal dosage
14 days
then 200 mg bd
Delavirdine* 400 mg tds NA
Efavirenz 600 mg daily Normal dosage
PIs
Saquinavir† 600 mg tds Normal dosage
Ritonavir 600 mg bd Normal dosage
Indinavir 800 mg bd Normal dosage
Nelfinavir 750 mg tds Normal dosage
Amprenavir 1 200 mg bd Normal dosage
* Drug should be administered after the haemodialysis session.
† When saquinavir is used in combination with ritonavir, its dose should be
reduced.
TABLE I. ORAL DOSAGE RECOMMENDATIONS FOR
ANTIRETROVIRAL DRUGS IN HEMODIALYSED PATIENTS12
Drug Abnormality 
NRTIs
Zidovudine Lactic acidosis, rhabdomyolysis
Didanosine Lactic acidosis, elevated serum uric 
acid
Zalcitabine Acute renal failure, lactic acidosis, 
hyponatraemia, hypocalcaemia, renal 
calculi





Saquinavir Lactic acidosis, hypocalcaemia, 
hypo/hyperkalaemia, magnesaemia 
and phosphoraemia, pancreatorenal 
syndrome
Ritonavir Acute renal failure, pancreatorenal 
syndrome, hypocalcaemia, 
hypo/hyperkalaemia
Indinavir Lactic acidosis, intratubular 
precipitation, urinary lithiasis, renal 
insufficiency
Nelfinavir Lactic acidosis, hypocalcaemia, lithiasis
TABLE II. RENAL ABNORMALITIES INDUCED BY
ANTIRETROVIRAL DRUGS13
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those HIV-positive patients who require dialysis, as HAART,
their young age and otherwise good health afford them an
excellent long-term prognosis.
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